Vosoritide Treatment in Children with Hypochondroplasia: Three-Year Results from a Phase 2 Extension Trial.
Vosoritide treatment in children with hypochondroplasia showed sustained improvements in height and growth velocity over three years, but results should be interpreted cautiously due to the small sample size.
Where it sits
this study against the rest of the vosoritide corpusSummary and findings
This study evaluated the safety and efficacy of vosoritide in children with hypochondroplasia over three years. Thirteen participants who previously demonstrated an increase in annualized growth velocity received daily subcutaneous vosoritide at a dose of 15 μg/kg/day. Results indicated improvements in height and growth velocity without new safety concerns.
Abstract
<h4>Purpose</h4>Vosoritide is a C-type natriuretic peptide analog approved for achondroplasia and under investigation for selected genetic causes of short stature. We previously reported the 12-months results of a phase 2 trial in children with hypochondroplasia (NCT04219007). Here, we report safety and efficacy outcomes from the three-year extension phase.<h4>Methods</h4>After completing a 6-month observation period followed by 12 months of daily subcutaneous vosoritide (15 μg/kg/day), participants with an increase in annualized growth velocity (AGV) >1.6 cm/year compared to baseline were eligible to continue in an open-label extension phase.<h4>Results</h4>Thirteen participants entered the extension phase and completed three years of treatment. Mean height SDS increased by 0.72 SD from Day 1 to Year 3, reaching -2.64±0.79 SD on the CDC growth charts. A similar increase was observed on the hypochondroplasia-specific charts (0.83 SD). Mean AGV increased from 4.27±0.70 cm/year at baseline to 7.24±0.80 cm/year at Year 1 and remained above baseline at Year 3 (6.13±1.27 cm/year). No new safety concerns were identified.<h4>Conclusion</h4>Vosoritide was associated with sustained improvements in growth in a selected cohort of initial good responders with hypochondroplasia. The treatment was well tolerated. Limitations of the extension study include selection bias and a small sample size.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.